Case Report: Extravazation of Therapeutic Yttrium-90-Ibritumomab Tiuxetan (Zevalin®): A Case Report
Publication: Cancer Biotherapy & Radiopharmaceuticals
Volume 21, Issue Number 2
Abstract
The occurrence of radiation necrosis to the extravasation of therapeutic radionuclide—yttrium-90-ibritumomab tiuxetan—is described, as well as the subsequent steps taken to both address the occurrence and to prevent the reoccurrence of such an adverse event. Published reports on the extravasation of diagnostic and therapeutic radionuclides are reviewed, as are prevention and treatment protocols.
Get full access to this article
View all available purchase options and get full access to this article.
Information & Authors
Information
Published In
Cancer Biotherapy & Radiopharmaceuticals
Volume 21 • Issue Number 2 • April 2006
Pages: 101 - 105
PubMed: 16706630
Copyright
Copyright 2006, Mary Ann Liebert, Inc.
History
Published online: 17 May 2006
Published in print: April 2006
Authors
Metrics & Citations
Metrics
Citations
Export Citation
Export citation
Select the format you want to export the citations of this publication.
View Options
Access content
To read the fulltext, please use one of the options below to sign in or purchase access.⚠ Society Access
If you are a member of a society that has access to this content please log in via your society website and then return to this publication.